Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 9/20 | 0.44 |
| ▸ | FPR2 | P25090 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | NPPA | P01160 | 1/20 | 0.41 |
| ▸ | MME | P08473 | 1/20 | 0.41 |
| ▸ | GRN | P28799 | 1/20 | 0.40 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27204662 | 1.00 | LMNA (0.46) | LMNASCN9AFPR2FFAR1TP53 | |
| SCHEMBL29123537 | 0.91 | MAPK1 (0.42) | LMNASCN9AFFAR1MAPTPPARG | |
| SCHEMBL24665448 | 0.90 | PPARD (0.44) | LMNASCN9AFPR2FFAR1PPARA | |
| SCHEMBL29123464 | 0.89 | SCN9A (0.41) | SCN9ATP53PPARALTA4HNPPA | |
| SCHEMBL30006191 | 0.89 | SCN9A (0.47) | LMNASCN9AFPR2FFAR1TP53 | |
| SCHEMBL29123609 | 0.89 | SCN9A (0.47) | LMNASCN9AFPR2FFAR1TP53 | |
| SCHEMBL27204735 | 0.89 | LTA4H (0.42) | SCN9AFPR2FFAR1MAPTSMN1; SMN2 | |
| SCHEMBL27171401 | 0.89 | LTA4H (0.42) | SCN9AFPR2FFAR1MAPTSMN1; SMN2 | |
| SCHEMBL30689299 | 0.84 | FFAR1 (0.51) | LMNASCN9AFPR2FFAR1TP53 | |
| SCHEMBL24664168 | 0.82 | SCN9A (0.43) | SCN9AFFAR1MAPTPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11932630-B2 | Heteroaryl aminopropanol derivatives | NOVARTIS AG (CH) | 2024-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11932630-B2 | Heteroaryl aminopropanol derivatives | CYP3A43, CYP11B2, ADRB3 | LMNA 3879/4885SCN9A 1338/4885FPR2 1570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.